Doxorubicin and Paclitaxel versus Fluorouracil, Doxorubicin and Cyclophosphamide as First-Line Therapy for Women with Advanced Breast Cancer: Long-Term Analysis of the Previously Published Trial

Publisher： Karger

E-ISSN： 2296-5262|32|8-9|468-472

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.32, Iss.8-9, 2009-07, pp. : 468-472

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase II Trial of Pegylated Liposomal Doxorubicin-Cyclophosphamide Combination as First-Line Chemotherapy in Older Metastatic Breast Cancer Patients

By  

Oncology, Vol. 73, Iss. 3-4, 2008-04 ,pp. : 210-214

Karger

Access to resources Recommend Favorite

Sequential Administration of Doxorubicin and Paclitaxel Followed by Cyclophosphamide, Methotrexate and 5-Fluorouracil Combination (CMF) in Women with Metastatic Breast Cancer

By  

Oncology, Vol. 55, Iss. 6, 1998-10 ,pp. : 533-537

Karger

Access to resources Recommend Favorite

Long‐term cardiac safety and outcomes of dose‐dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer

By  

CANCER, Vol. 119, Iss. 22, 2013-11 ,pp. : 3943-3951

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase II Study of Bolus 5-Fluorouracil and Leucovorin Combined with Weekly Paclitaxel as First-Line Therapy for Advanced Gastric Cancer

By  

Oncology, Vol. 81, Iss. 5-6, 2011-11 ,pp. : 291-297

Karger

Access to resources Recommend Favorite

A Phase II Trial of Irinotecan, 5-Fluorouracil and Leucovorin Combined with Celecoxib and Glutamine as First-Line Therapy for Advanced Colorectal Cancer

By  

Oncology, Vol. 69, Iss. 1, 2005-09 ,pp. : 63-70

Karger

Access to resources Recommend Favorite